Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Journal Information
Full Title: Cancer
Abbreviation: Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Disclosures Hossein Borghaei receives partial support from the National Institutes of Health (P30 CA006927); has received clinical trial research support from Millennium Pharmaceuticals, Merck, Celgene, Bristol‐Myers Squibb, and Lilly; has served on an advisory board or as a consultant for Bristol‐Myers Squibb, Lilly, Genentech, Celgene, Pfizer, Merck, EMD Serono, Boehringer Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, AbbVie, Axiom, PharmaMar, Takeda, Huya Bioscience International, GLG Pharma, and Daiichi‐Sankyo; has served on data and safety monitoring boards for the University of Pennsylvania chimeric antigen receptor T‐cell program, Takeda, and Incyte; has served on scientific advisory boards for Sonnet BioTherapeutics and Rgenix; owns stock in Sonnet BioTherapeutics and Rgenix; and is an employee of Fox Chase Cancer Center. Corey J. Langer has served as a consultant for/received honoraria from Boehringer Ingelheim, Novocure, AstraZeneca, Takeda, Genentech/Roche, Merck, Gilead Sciences, GlaxoSmithKline, OncLive, Takai, and RTP; has received research funding from Advantagene, AstraZeneca, Genentech/Roche, Lilly, Takai, Trizell, Merck, Takeda, and Inovio Pharmaceuticals; has received medical writing support from Novartis; and has served on data and safety monitoring committees for Lilly, Amgen, and SWOG. Luis Paz‐Ares reports honoraria (to him/spouse) for scientific advice or speaking from Advanced Accelerator Applications (Adacap), Amgen, AstraZeneca, Bayer, Blueprint Medicines, Bristol‐Myers Squibb, Boehringer Ingelheim, Celgene, Incyte, Ipsen, Lilly, Merck, MSD, Novartis, PharmaMar, Pfizer, Roche, Sanofi, Servier, Takeda, and Sysmex; is a board member for Genomica and Altum Sequencing; and reports grants to his institution from AstraZeneca, Bristol‐Myers Squibb, MSD, and Pfizer. Delvys Rodríguez‐Abreu reports grants from Bristol‐Myers Squibb and has received honoraria for lectures and consulting from Bristol‐Myers Squibb, Genentech/Roche, MSD, AstraZeneca, Boehringer Ingelheim, Lilly, Roche, Novartis, and Pfizer. Balazs Halmos has received research funding from Amgen, Janssen, Advaxis, Merck, Bristol‐Myers Squibb, Boehringer‐Ingelheim, Lilly, Novartis, GlaxoSmithKline, Pfizer, AbbVie, AstraZeneca, Mirati Therapeutics, Takeda, and Guardant Health; has served as a consultant for Merck, Novartis, Boehringer Ingelheim, AstraZeneca, Novartis, Pfizer, Guardant Health, Spectrum, Bristol‐Myers Squibb, and Genentech; and has received personal fees from Amgen and TPT. Marina C. Garassino has received grants and personal fees for clinical trials from AstraZeneca, Novartis, Bristol‐Myers Squibb, Roche, Pfizer, Celgene, Bayer, and MSD; grants from Turning Point, Ipsen, MedImmune, Exelixis, Incyte, Lilly, Otsuka Pharmaceutical, Tiziana Life Sciences, Clovis Oncology, Merck Serono, Merck KGaA, Blueprint Medicine, GlaxoSmithKline, United Therapeutics Corporation, and Spectrum Pharmaceuticals; personal fees from Seattle Genetics, Daiichi Sankyo, GlaxoSmithKline, Lilly, Janssen, Boehringer Ingelheim, Blueprint Medicine, Otsuka Pharmaceutical, Incyte, Inivata, Spectrum Pharmaceuticals, Takeda, and Sanofi‐Aventis; and nonfinancial support from MSD, Pfizer, and Lilly. Takayasu Kurata has received honoraria from AstraZeneca, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Chugai, Lilly, MSD, and Ono Pharmaceutical and reports grants from AstraZeneca, MSD, Bristol‐Meyers Squibb, Novartis, Takeda, and Chugai. Jianxin Lin is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, USA. M. Catherine Pietanza is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, USA and owns stock in Merck & Co., Inc., Kenilworth, New Jersey, USA. Bilal Piperdi is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, USA. and owns stock in Merck & Co, Inc., Kenilworth, New Jersey, USA. Shirish M. Gadgeel has received personal fees from AstraZeneca, Daichii‐Sankyo, Genentech/Roche, Takeda/Ariad, Boehringer Ingelheim, Merck, Novocure, Bristol‐Myers Squibb, AbbVie, Jazz Pharmaceuticals, and Xcovery. The other authors made no disclosures."
"We thank the patients and their families and caregivers for participating in the studies included in this pooled analysis along with all investigators and site personnel. Medical writing assistance was provided by Sheri Arndt, PharmD, and Mariana Ovnic, PhD, of ICON plc (North Wales, Pennsylvania). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Kenilworth, New Jersey)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025